文 献12）Tanaka H, Kubo M, Nii M, Maki S, Umekawa T, Ikeda T. Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction. J Obstet Gynaecol Res 2017; 43(7): 1205-8.13）Yoshikawa K, Umekawa T, Maki S, Kubo M, Nii M, Tanaka K, et al. Tadalafil Improves L-NG Nitroarginine Methyl Ester-Induced Preeclampsia With Fetal Growth Restriction-Like Symptoms in Pregnant Mice. Am J Hypertens 2017; 31(1): 89-96.14）Miller SL, Huppi PS, Mallard C. The consequences of fetal growth restriction on brain structure and neurodevelopmental outcome. J Physiol 2016; 594(4): 807–23.15）Maki S, Tanaka H, Tsuji M, Furuhashi F, Magawa S, Kaneda MK, et al. Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction(TADAFER): Results from the PhaseⅡ Trial. J Clin Med 2019; 8(6): pii: E856.16）Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny LC, et al. Maternal sildenafil for severe fetal growth restriction(STRIDER): a multicenter, randomized, placebo-controlled, double-blind trial. Lancet Child Adolesc Health 2018; 2(2): 93-102.17）Tachibana R, Umekawa T, Yoshikawa K, Owa T, Magawa S, Furuhashi F, et al. Tadalafil treatment in mice for preeclampsia with fetal growth restriction has neuro-benefic effects in offspring through modulating prenatal hypoxic conditions. Sci Rep 2019; 9(1): 234.18）Groom KM, Ganzevoort W, Alfirevic Z, Lim K, Papageorghiou AT; STRIDER Consortium. Clinicians should prescribing sildenafil for fetal growth restriction(FGR): comment from the STRIDER Consortium. Ultrasound Obstet Gynecol 2018; 52(3): 295-6.19）Walton RB, Reed LC, Estrada SM, Schmiedecke SS, Villazana-Kretzer DL , Napolitano PG, et al. Evaluation of Sildenafil and Tadalafil for Reversing Constriction of Fetal Arteries in Human Placenta Perfusion Model. Hypertension 2018; 72(1): 1677-6.601）Temming LA, Dicke JM, Stout MJ, Rampersad RM, Macones GA, Tuuli MG, et al. Early Second-Trimester Fetal Growth Restriction and Adverse Perinatal Outcomes. Obstet Gynecol 2017; 130(4): 865-9.2）Maeyama K, Morioka I, Iwatani S, Fukushima S, Kurokawa D, Yamana K, et al. Gestational age-dependency of height and body mass index trajectories during the first 3 years in Japanese small-for-gestational age children. Sci Rep 2016; 6: 38659.3）Baschat AA. Neurodevelopment after fetal growth restriction. Fetal Diagn Ther 2014; 36(2): 136-42.4）Gluckman PD, HansonMA. Living with the past: evolution, development, and patterns of disease. Science 2004; 305(5691): 1733-6.5）Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308(5728): 1592-4.6）Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002; 1(9): 674-82.7）Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006; 61(3): 280-8.8）Viagra, INN-sildenafil - WC500049826.pdf. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000202/WC500049826.pdf（Accessed August 4, 2019）9）ADCIRCA, INN - Tadalafil - WC500032789.pdf. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001021/WC500032789.pdf（Accessed August 4, 2019）10）Kubo M, Umekawa T, Maekawa Y, Tanaka H, Nii M, Murabayashi N, et al. Retrospective study of tadalafil for fetal growth restriction: Impact on maternal and perinatal outcomes. J Obstet Gynaecol Res 2017; 43(2): 291-7.11）Kubo M, Tanaka H, Maki S, Nii M, Murabayashi N, Osato K, et al. Safety and dose-finding trial of administered for fetal growth restriction: A phase-1 clinical study. J Obstet Gynaecol Res 2017; 43(7): 1159-68.
元のページ ../index.html#74